TABLE 1.
Summary of efficacy induced by the PvCelTOS vaccination regimens using Ad, MVA, protein, or Qβ VLPs in mice challenged by wild-type or transgenic P. berghei sporozoites
| Challenge (1,000 sporozoites) | Vaccine regimen | Mouse strain | No. of mice protected/total no. tested | % of mice with sterile protection | Survival duration (days) |
|||
|---|---|---|---|---|---|---|---|---|
| Median | Range | Mean ± SD | SE | |||||
| Pb-PvCelTOS, transgenic | ChAd63-protein | CD-1 | 3/10 | 30 | 6.61 | 6.25–14.0 | 8.77 ± 3.6 | 1.14 |
| ChAd63-VLPs | CD-1 | 3/10 | 30 | 7.15 | 5.80–14.0 | 8.96 ± 3.5 | 1.11 | |
| ChAd63-MVA | CD-1 | 1/10 | 10 | 6.33 | 5.80–14.0 | 7.12 ± 2.5 | 0.78 | |
| Nonea | CD-1 | 0/10 | 0 | 6.105 | 5.72–6.56 | 6.09 ± 0.2 | 0.07 | |
| Pb-PfCelTOS, transgenic | ChAd63-protein | CD-1 | 2/10 | 20 | 6.58 | 5.84–14.0 | 7.97 ± 3.2 | 1.01 |
| ChAd63-VLPs | CD-1 | 0/10 | 0 | 6.535 | 6.18–7.76 | 6.63 ± 0.4 | 0.14 | |
| ChAd63-MVA | CD-1 | 0/10 | 0 | 6.365 | 5.80–7.54 | 6.44 ± 0.6 | 0.18 | |
| None | CD-1 | 0/10 | 0 | 6.085 | 5.75–6.75 | 6.18 ± 0.3 | 0.09 | |
| P. berghei wild type | ChAd63-protein | CD-1 | 0/20 | 0 | 6.59103 | 5.0–8.0 | 6.66 ± 0.9 | 0.31 |
| ChAd63-VLPs | CD-1 | 0/8 | 0 | 6.35623 | 5.0–9.0 | 6.75 ± 1.2 | 0.41 | |
| ChAd63-MVA | CD-1 | 0/16 | 0 | 5.74167 | 4.99–6.69 | 5.81 ± 1.2 | 0.19 | |
| None | CD-1 | 0/19 | 0 | 6 | 5.56–7.12 | 6.13 ± 0.6 | 0.21 | |
| Pb-PvCelTOS, transgenic | ChAd63-protein | BALB/c | 0/6 | 0 | 5.72106 | 5.63–7.24 | 5.99 ± 0.6 | 0.26 |
| ChAd63-VLPs | BALB/c | 0/6 | 0 | 5.95633 | 5.56–6.43 | 5.95 ± 0.3 | 0.13 | |
| ChAd63-MVA | BALB/c | 0/6 | 0 | 5.77731 | 5.62–6.08 | 5.82 ± 0.2 | 0.07 | |
| None | BALB/c | 0/6 | 0 | 5.74162 | 3.84–5.90 | 5.45 ± 0.8 | 0.33 | |
a
The mice tested were naive.